摘要:
Compounds of formula (I) are described in which Het is a five or six membered heteroaromatic ring of the formula in which one of R1 and R2 is optionally substituted heteroaryl and the other is optionally substituted heteroaryl or optionally substituted aryl; X1 is a bond, X3 and X4 are each independently N or C and X2 and X5 are independently CH, N, NH, O or S; or X3 and X4 are C, one of X1, X2 and X5 is N and the others are N or CH; but excluding compounds in which X1 is a bond, one of X2 and X5 is N and the other is NH and X3 and X4 are both C; R3 represents a group -L1-R6; R4 represents hydrogen, alkyl or hydroxyalkyl; or R3 and R4, when attached to the same carbon atom, may form with the said carbon atom a cycloalkyl, cycloalkenyl or heterocycloalkyl ring or a group C═CH2; R5 represents hydrogen or alkyl; and m is zero or an integer 1 or 2; and N-oxides thereof, and their prodrugs; and pharmaceutically acceptable salts and solvates of compounds of formula (I) and N-oxides thereof, and their prodrugs. The compounds are TNF inhibitors and are useful as pharmaceuticals.
摘要:
Compounds of formula (I) are described in which Het is a five or six membered heteroaromatic ring of the formula in which one of R1 and R2 is optionally substituted heteroaryl and the other is optionally substituted heteroaryl or optionally substituted aryl; X1 is a bond, X3 and X4 are each independently N or C and X2 and X5 are independently CH, N, NH, O or S; or X3 and X4 are C, one of X1, X2 and X5 is N and the others are N or CH; but excluding compounds in which X1 is a bond, one of X2 and X5 is N and the other is NH and X3 and X4 are both C; R3 represents a group -L1-R6; R4 represents hydrogen, alkyl or hydroxyalkyl; or R3 and R4, when attached to the same carbon atom, may form with the said carbon atom a cycloalkyl, cycloalkenyl or heterocycloalkyl ring or a group C═CH2; R5 represents hydrogen or alkyl; and m is zero or an integer 1 or 2; and N-oxides thereof, and their prodrugs; and pharmaceutically acceptable salts and solvates of compounds of formula (I) and N-oxides thereof, and their prodrugs. The compounds are TNF inhibitors and are useful as pharmaceuticals.
摘要:
This invention is directed to compounds of formula I ##STR1## wherein R.sup.1 is CN, CH.sub.2 CN, CH.dbd.CHCN, CHO, or CH.dbd.CHCO.sub.2 H;R.sup.2 is aryl lower alkoxy, heteroaryl lower alkoxy, aryl lower alkylthio or heteroaryl lower alkylthio wherein each of the aryl and heteroaryl moieties is optionally substituted;R.sup.3 is halogen;R.sup.4 is optionally substituted aryl or optionally substituted heteroaryl;R.sup.5 is carboxy or an acid isostere;X is oxygen or sulphur; andn is zero or 1; or an N-oxide thereof, prodrug thereof solvate thereof, or pharmaceutically acceptable salt thereof, which compounds have endothelin antagonist activity. The invention is also directed to methods for preparing the compounds of formula I and their pharmaceutical use.
摘要翻译:本发明涉及式Ⅰ化合物,其中R1是CN,CH2CN,CH = CHCN,CHO或CH = CHCO2H; R 2是芳基低级烷氧基,杂芳基低级烷氧基,芳基低级烷硫基或杂芳基低级烷硫基,其中芳基和杂芳基部分中的每一个任选被取代; R3是卤素; R 4是任选取代的芳基或任选取代的杂芳基; R5是羧基或酸等isostere; X是氧或硫; n为0或1; 或其N-氧化物,其前体药物溶剂化物或其药学上可接受的盐,该化合物具有内皮素拮抗剂活性。 本发明还涉及制备式I化合物及其药物用途的方法。
摘要:
This invention is directed to compounds of formula I ##STR1## wherein R.sup.1 is CN, CH.sub.2 CN, CH.dbd.CHCN, CHO, or CH.dbd.CHCO.sub.2 H;R.sup.2 is aryl lower alkoxy, heteroaryl lower alkoxy, aryl lower alkylthio or heteroaryl lower alkylthio wherein each of the aryl and heteroaryl moieties is optionally substituted;R.sup.3 is halogen;R.sup.4 is optionally substituted aryl or optionally substituted heteroaryl;R.sup.5 is carboxy or an acid isostere;X is oxygen or sulphur; andn is zero or 1; or an N-oxide thereof, prodrug thereof solvate thereof, or pharmaceutically acceptable salt thereof, which compounds have endothelin antagonist activity. The invention is also directed to methods for preparing the compounds of formula I and their pharmaceutical use.
摘要翻译:本发明涉及式Ⅰ化合物,其中R1是CN,CH2CN,CH = CHCN,CHO或CH = CHCO2H; R 2是芳基低级烷氧基,杂芳基低级烷氧基,芳基低级烷硫基或杂芳基低级烷硫基,其中芳基和杂芳基部分中的每一个任选被取代; R3是卤素; R 4是任选取代的芳基或任选取代的杂芳基; R5是羧基或酸等isostere; X是氧或硫; n为0或1; 或其N-氧化物,其前体药物溶剂化物或其药学上可接受的盐,该化合物具有内皮素拮抗剂活性。 本发明还涉及制备式I化合物及其药物用途的方法。